At a glance
ClinicalIndex Comparison Record- ✓Receiving PAXLOVID (nirmatrelvir/ritonavir)
- ✓No prior history of PAXLOVID use
None specified.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
General Investigation for PAXLOVID PAC
In Brief
An observational study evaluating nirmatrelvir / ritonavir for SARS-CoV-2 Infection. Completed, enrolled 3,346 participants across 1 site.
Detailed Summary
The purpose of this post marketing observational study is to learn about the safety and effects of the commercial medicine (called PAXLOVID) for the treatment of COVID-19. This study is intended to be registered with the participants who: * Have taken PAXLOVID PACK and have no history of using this medicine. * Are 12 years and older All participants will receive PAXLOVID, a standard treatment for COVID-19. Participants will take PAXLOVID 2 times a day by mouth or as prescribed. We will examine the experiences of people taking PAXLOVID. This will help us determine if PAXLOVID is safe and effective. Participants will be followed up for 28 days after taking PAXLOVID. During this time, participants will be closely watched for the safety and effects of PAXLOVID.
Study Details
Timeline
Interventions
The usual dosage in adults and pediatric patients (≥12 years of age weighing ≥40 kg) is 300 mg of Nirmatrelvir and 100 mg of ritonavir all taken together orally twice daily for 5 days.